-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
Nektar Therapeutics quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2010 to 2023.
- Nektar Therapeutics Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$37.1M, a 19.2% increase year-over-year.
- Nektar Therapeutics Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$168M, a 42.7% increase year-over-year.
- Nektar Therapeutics annual Net Income (Loss) Attributable to Parent for 2023 was -$276M, a 25% increase from 2022.
- Nektar Therapeutics annual Net Income (Loss) Attributable to Parent for 2022 was -$368M, a 29.7% increase from 2021.
- Nektar Therapeutics annual Net Income (Loss) Attributable to Parent for 2021 was -$524M, a 17.9% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)